SEC Form 4Coverage since Jun 1, 2026
$RCUS insider trading
Over the last 12 months, Arcus Biosciences insiders reported no purchases and 3 sales totaling $3.0M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.0M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $RCUS · 12Mvia TradingView
Top insiders · 12m
Jaen Juan C.President2× · $2.9M
Azoy AlexanderChief Accounting Officer1× · $66K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Jaen Juan C.President · O | ▼ Sale | 68,569 | $29.63 | $2.0M | -7.7% | plan · 3 tranches · indirect |
| Jun 24, 2026 | Jaen Juan C.President · O | ▼ Sale | 31,431 | $27.92 | $878K | -3.4% | plan · 4 tranches · indirect |
| Jun 1, 2026 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 2,562 | $25.77 | $66K | -6.1% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RCUS feed.